Key Highlights

  • Sonic Healthcare (ASX:SHL) traded at A$20.06 during the 6 November 2026 session, up 0.91%.
  • FY26 Revenue was A$10,867 million, up 13%, and underlying EBITDA was A$1,933 million, up 11%.
  • Underlying net profit was A$621 million, up 17%, and underlying EPS was 125.6 cents, up 14%.

Sonic Healthcare (ASX:SHL) shares were quoted at A$20.06 during the 6 November 2026 trading session, up 0.91%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 20 August 2026 FY26 release. Sonic is a global provider of pathology and diagnostic imaging services, listed on the ASX and with an ADR in the United States.

Latest Developments

FY26 Full-Year Results (released 20 August 2026)

Sonic reported revenue of A$10,867 million for the year to 30 June 2026, up 13%, and underlying EBITDA of A$1,933 million, up 11%. Statutory EBITDA was A$1,882 million, and underlying net profit was A$621 million, up 17%, with statutory net profit of A$608 million. The company said it achieved its underlying EBITDA guidance through revenue growth, Operating Leverage and synergy realisation, while maintaining disciplined Capital management.

About the Company

Sonic Healthcare is an ASX-listed pathology and diagnostic imaging company with operations in several countries. Its ADR trades in the United States under SKHHY.

Business Overview

Sonic's Business includes laboratory pathology testing and diagnostic imaging services. Growth in the year came from revenue expansion, operating leverage and the realisation of Acquisition synergies.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Pathology and imaging providers are sensitive to test volumes, government funding and labour costs. Sonic's FY26 release emphasised operating leverage, which is relevant when volumes grow faster than costs.

Risks to Watch

Pathology and imaging revenue depends on patient test volumes and government funding arrangements, which can change. Labour costs, acquisition integration and currency movements are further factors that could affect future results.

Catalysts on Watch

Investors may follow Sonic's next half-year result, updates on synergy realisation and any change to Medicare or other funding settings.

Final Takeaways

Sonic Healthcare (ASX:SHL) traded higher on 6 November 2026 in a session where the health care index eased. Its FY26 release, published on 20 August 2026, reported higher revenue and earnings, and is separate from the session move.